Overview
- Full-year revenue reached $58.7 billion as net profit rose to $10.2 billion, driven largely by higher cancer drug sales.
- For 2026, the company guides to mid-to-high single-digit total revenue growth and low double-digit core earnings per share growth.
- Oncology remained the main engine: oncology revenue increased 14% to $25.6 billion, with Tagrisso at $7.25 billion, Imfinzi at $6.06 billion, and Enhertu up 40% to $2.78 billion.
- Management highlights more than 100 ongoing Phase 3 studies and expects over 20 late-stage readouts during 2026.
- Strategic moves include a $15 billion China investment pledge, an $18.5 billion CSPC partnership for weight-loss and diabetes drugs, a direct NYSE listing, and a planned $50 billion US buildout linked to a three-year tariff reprieve under a White House pricing deal.